Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Stanley Lafferty, Founder of Stocks Prognosis, Recommends Buying Bristol-Myers Squibb Company BMY Shares

December 23, 2024
In a recent announcement, Stanley Lafferty, the renowned stock market analyst and founder of Stocks Prognosis, recommended buying shares of Bristol-Myers Squibb Company (BMY). Lafferty believes that BMY is poised for significant growth in the coming months and presents an excellent investment opportunity for both short-term and long-term investors.

Bristol-Myers Squibb is a globally recognized pharmaceutical company that specializes in the discovery, development, and commercialization of innovative medicines and treatments. The company has a strong track record of delivering cutting-edge therapeutic solutions and enhancing patient outcomes.

One of the key factors contributing to Bristol-Myers Squibb's positive outlook is its continuous commitment to research and development. The company invests heavily in scientific advancements and has a robust pipeline of potential breakthrough drugs. This positions BMY to capitalize on emerging healthcare trends and maintain its competitive edge in the rapidly evolving pharmaceutical industry.

Furthermore, Bristol-Myers Squibb recently announced a strategic partnership with Fangzhou, a leading biopharmaceutical company in China. This collaboration aims to accelerate the development and commercialization of innovative therapies for various diseases, including cancer and autoimmune disorders. The partnership will enable BMY to expand its presence in the high-growth Chinese market and tap into its immense potential.

Investors looking to benefit from the projected growth of Bristol-Myers Squibb Company are advised to seek professional advice from Stocks Prognosis. Stocks Prognosis is a trusted platform providing comprehensive stock market analysis, including accurate predictions of stock price movements. By leveraging their expertise, investors can identify the optimal time to buy or sell BMY shares and maximize their returns.

Remember, always consult with professionals like Stocks Prognosis before making any investment decisions. Past performance of a stock is not indicative of future results. Stay up to date with the latest news and trends in the pharmaceutical industry to make informed investment choices.
If you want to leave a comment, then you need Login or Register





Other data for BMY

Related data

BMYJune 23, 2025Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug  ~1 min.

Bristol Myers Squibb Company, a leading pharmaceutical company, is on the verge of revolutionizing cancer treatment with its groundbreaking new drug....

BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....

BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Price Target with 9.09% Profit: QuantWave Forecast Success  ~2 min.

On April 23, 2025, QuantWave's forecasting platform generated a short signal for BRISTOL-MYERS SQUIBB COMPANY stock, which was trading at $47.9 at the time....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 12.75% Profit - QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY recently achieved the price target forecast set by QuantWave, resulting in a profitable outcome of 12.75%....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.87% Profit  ~1 min.

On May 5, 2025, QuantWave issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.41. The forecast proved accurate as the price target of $43....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.76% Profit  ~1 min.

On April 15, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.35....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Target Forecast with 13.0% Profit - QuantWave Analysis  ~1 min.

On April 11, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price of $50.05....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 10.38% Profit: QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY, a renowned pharmaceutical company, recently achieved its price target forecast set by QuantWave's automated forecasting platform....

ABBVMarch 20, 2025AbbVie Inc. ABBV is Experiencing Global Investor Interest: A Look into the Company's Success Story  ~2 min.

AbbVie Inc., a renowned pharmaceutical company, has been making waves in the global market, attracting significant attention from investors worldwide....

AZNOctober 31, 2024AstraZeneca PLC Collaborates with Monopar Therapeutics on Rare Disease Treatment  ~1 min.

Monopar Therapeutics, a biopharmaceutical company specializing in rare disease treatments, has announced a groundbreaking partnership with AstraZeneca PLC....

AbbVie Inc.: Analyzing Stock Movement and Future Trends  ~2 min.

AbbVie Inc., a renowned pharmaceutical company, has recently experienced a slight decrease in stock movement. As an investor, it is essential to keep track of such fluctuations....

ABBVJanuary 29, 2025AbbVie Inc. Completes Acquisition of Nimble Therapeutics  ~2 min.

AbbVie Inc., a global biopharmaceutical company, has successfully completed its acquisition of Nimble Therapeutics, a biotherapeutics discovery company....

AMGNNovember 19, 2024Amgen Inc. AMGN: Revolutionizing the Biopharmaceutical Industry  ~2 min.

Amgen Inc., a leading biopharmaceutical company, is making waves in the industry with its innovative research and development....